NIH UG3 funding opportunities: Exploratory/Developmental Phase I Cooperative Agreement
17 NIH notices for UG3 (Exploratory/Developmental Phase I Cooperative Agreement) are open and 3 forecast. The first phase of a phased cooperative agreement....
- Open notices17
- Forecast3
- Projects funded under them7,148
Open NIH UG3 notices
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Open - Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Open - Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Open - NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Open - Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Open - Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Open - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Open - Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
Open - NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Open - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Open - Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Open - Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Open - Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Open - Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)
Open - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Open - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Open - NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
Open
Forecast UG3 notices
- HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Forecast - Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
Forecast - Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Forecast
Institutes that fund UG3 projects under these notices
| Institute or center | Projects |
|---|---|
| National Cancer Institute (NCI) | 1,050 |
| National Heart Lung and Blood Institute (NHLBI) | 797 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 661 |
| National Institute on Aging (NIA) | 599 |
| National Institute of General Medical Sciences (NIGMS) | 590 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 541 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 456 |
| National Institute on Drug Abuse (NIDA) | 352 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 304 |
| National Institute of Mental Health (NIMH) | 290 |
Closed UG3 notices
- RFA-RM-27-012: PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
- RFA-RM-27-013: Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
- RFA-NS-25-021: BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
- PAR-25-051: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- PAR-24-275: Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)
- PAR-24-312: Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
- PAR-25-049: NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
- PAR-25-170: Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)
- PAR-24-123: Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
- PAR-25-029: Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- PAR-25-023: Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
- PAR-25-072: Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
- RFA-HL-26-006: Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
- PAR-25-048: Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
- PAR-25-329: Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
- PAR-25-034: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
- RFA-CA-25-013: Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
- PAR-24-064: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
- RFA-NS-24-019: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
- RFA-EB-25-002: Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed)
- PAR-25-054: NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
- RFA-RM-24-012: In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
- PA-23-189: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
- PAR-22-192: Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- RFA-AG-25-027: Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional)
- PAR-21-237: NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
- PAR-21-160: NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- PAR-22-076: Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
- PAR-22-200: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
- PAR-23-253: Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
- PAR-24-043: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- PAR-24-208: NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- RFA-CA-25-009: Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required)
- RFA-CA-25-010: Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
- PAR-21-317: NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- PAR-23-087: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
- PAR-23-274: Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- PAR-24-101: NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- PAR-22-256: Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
- PAR-22-142: NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
- PAR-23-090: NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
- RFA-NS-24-041: NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional)
- RFA-AT-24-011: HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
- RFA-NS-24-016: BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
- RFA-HL-25-010: Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)
- RFA-MH-25-190: Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
- RFA-TR-24-025: Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)
- PAR-22-167: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
- PAR-22-209: CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
- RFA-EB-23-006: Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs) (UG3/UH3 Clinical Trial Not Allowed)
- RFA-AG-25-004: Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)
- RFA-NS-24-023: HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 - Clinical Trial Optional)
- RFA-CA-23-028: Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
- PAR-21-315: Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
- PAR-21-163: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- PAR-24-053: Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required)
- RFA-AI-24-009: Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of HIV Among People Who Are at Increased Risk for HIV Infection in Latin America (LITE-LA) (UG3/UH3 Clinical Trial Optional)
- RFA-HG-24-004: ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed)
- RFA-HG-24-005: ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed)
- PAR-24-090: Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)
- RFA-DA-25-028: Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)
- RFA-CA-23-029: Cancer Immunoprevention Network (CIP-Net) ?Research Projects (UG3/UH3 Clinical Trials Not Allowed)
- PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- RFA-HG-22-027: Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)
- RFA-AI-24-002: Research Initiative for Vaccine and Antibiotic Allergy (UG3/UH3 Clinical Trial Not Allowed)
- RFA-MH-23-295: BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)
- RFA-MH-24-120: Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
- RFA-DK-23-004: Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)
- RFA-AI-23-060: Engineering and Preclinical Development of Biological Products that Eliminate HIV-infected Cells (UG3/UH3 Clinical Trial Not Allowed)
- PAR-21-243: Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)
- RFA-CA-24-021: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
- RFA-DA-25-058: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
- RFA-NS-21-021: Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)
- RFA-NS-21-023: BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
- RFA-AG-24-027: Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed)
- PAR-21-183: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
- RFA-NS-24-018: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
- RFA-EB-22-003: BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)
- RFA-AT-24-004: NIH-DoD-VA Pain Management Collaboratory ? Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
- RFA-CA-22-029: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
- RFA-CA-22-028: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)
- RFA-AI-23-021: Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed)
- RFA-MH-22-115: BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)
- PAR-23-066: Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Required)
- RFA-NS-22-050: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
- RFA-DA-23-049: HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 - Clinical Trial Optional)
- PAR-22-169: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
- RFA-EB-22-001: BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)
- RFA-OD-22-017: Open Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3)
- RFA-DE-23-009: Harnessing Technologies to Support Oral Health Promotion and Management Outside the Dental Setting (UG3/UH3 Clinical Trial Required)
- RFA-AT-23-002: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
- RFA-AT-23-001: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
- RFA-OD-22-019: Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3)
- RFA-OD-22-018: Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy and Pediatric Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3)
- RFA-NR-23-001: HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required)
- RFA-RM-22-016: Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)
- RFA-NS-22-053: NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional)
- RFA-AT-23-003: Fostering Mental, Emotional, and Behavioral (MEB) Health Among Children in School Settings: Opportunities for Multisite Trials of Complementary and Integrative Health Interventions (Clinical Trial Optional)
- RFA-HL-23-015: New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed)
- RFA-HL-23-017: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Questions people ask
What is an NIH UG3?
UG3 is NIH's activity code for the Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Each notice sets its own budget limit, project length and due dates.
How many NIH UG3 funding opportunities are open?
17 notices are open on Grants.gov, and 3 more are forecast, as of the latest data.